IBDEI026 ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,466,1,3,0)
 ;;=3^Anaplastic large cell lymphoma, ALK-negative, unsp site
 ;;^UTILITY(U,$J,358.3,466,1,4,0)
 ;;=4^C84.70
 ;;^UTILITY(U,$J,358.3,466,2)
 ;;=^5001661
 ;;^UTILITY(U,$J,358.3,467,0)
 ;;=C84.79^^2^21^9
 ;;^UTILITY(U,$J,358.3,467,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,467,1,3,0)
 ;;=3^Anaplstc lg cell lymph, ALK-neg, extrnod and solid org sites
 ;;^UTILITY(U,$J,358.3,467,1,4,0)
 ;;=4^C84.79
 ;;^UTILITY(U,$J,358.3,467,2)
 ;;=^5001670
 ;;^UTILITY(U,$J,358.3,468,0)
 ;;=C91.40^^2^21^32
 ;;^UTILITY(U,$J,358.3,468,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,468,1,3,0)
 ;;=3^Hairy cell leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,468,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,468,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,469,0)
 ;;=C91.41^^2^21^34
 ;;^UTILITY(U,$J,358.3,469,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,469,1,3,0)
 ;;=3^Hairy cell leukemia, in remission
 ;;^UTILITY(U,$J,358.3,469,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,469,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,470,0)
 ;;=C91.42^^2^21^33
 ;;^UTILITY(U,$J,358.3,470,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,470,1,3,0)
 ;;=3^Hairy cell leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,470,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,470,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,471,0)
 ;;=C96.4^^2^21^58
 ;;^UTILITY(U,$J,358.3,471,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,471,1,3,0)
 ;;=3^Sarcoma of dendritic cells (accessory cells)
 ;;^UTILITY(U,$J,358.3,471,1,4,0)
 ;;=4^C96.4
 ;;^UTILITY(U,$J,358.3,471,2)
 ;;=^5001861
 ;;^UTILITY(U,$J,358.3,472,0)
 ;;=C96.9^^2^21^43
 ;;^UTILITY(U,$J,358.3,472,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,472,1,3,0)
 ;;=3^Malig neoplm of lymphoid, hematpoetc and rel tissue, unsp
 ;;^UTILITY(U,$J,358.3,472,1,4,0)
 ;;=4^C96.9
 ;;^UTILITY(U,$J,358.3,472,2)
 ;;=^5001864
 ;;^UTILITY(U,$J,358.3,473,0)
 ;;=C90.00^^2^21^51
 ;;^UTILITY(U,$J,358.3,473,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,473,1,3,0)
 ;;=3^Multiple myeloma not having achieved remission
 ;;^UTILITY(U,$J,358.3,473,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,473,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,474,0)
 ;;=C90.01^^2^21^50
 ;;^UTILITY(U,$J,358.3,474,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,474,1,3,0)
 ;;=3^Multiple myeloma in remission
 ;;^UTILITY(U,$J,358.3,474,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,474,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,475,0)
 ;;=C90.02^^2^21^49
 ;;^UTILITY(U,$J,358.3,475,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,475,1,3,0)
 ;;=3^Multiple myeloma in relapse
 ;;^UTILITY(U,$J,358.3,475,1,4,0)
 ;;=4^C90.02
 ;;^UTILITY(U,$J,358.3,475,2)
 ;;=^5001753
 ;;^UTILITY(U,$J,358.3,476,0)
 ;;=C91.00^^2^21^1
 ;;^UTILITY(U,$J,358.3,476,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,476,1,3,0)
 ;;=3^Acute lymphoblastic leukemia not having achieved remission
 ;;^UTILITY(U,$J,358.3,476,1,4,0)
 ;;=4^C91.00
 ;;^UTILITY(U,$J,358.3,476,2)
 ;;=^5001762
 ;;^UTILITY(U,$J,358.3,477,0)
 ;;=C91.01^^2^21^3
 ;;^UTILITY(U,$J,358.3,477,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,477,1,3,0)
 ;;=3^Acute lymphoblastic leukemia, in remission
 ;;^UTILITY(U,$J,358.3,477,1,4,0)
 ;;=4^C91.01
 ;;^UTILITY(U,$J,358.3,477,2)
 ;;=^5001763
 ;;^UTILITY(U,$J,358.3,478,0)
 ;;=C91.02^^2^21^2
 ;;^UTILITY(U,$J,358.3,478,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,478,1,3,0)
 ;;=3^Acute lymphoblastic leukemia, in relapse
 ;;^UTILITY(U,$J,358.3,478,1,4,0)
 ;;=4^C91.02
 ;;^UTILITY(U,$J,358.3,478,2)
 ;;=^5001764
 ;;^UTILITY(U,$J,358.3,479,0)
 ;;=C91.10^^2^21^13
 ;;^UTILITY(U,$J,358.3,479,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,479,1,3,0)
 ;;=3^Chronic lymphocytic leuk of B-cell type not achieve remis
 ;;
 ;;$END ROU IBDEI026
